[HTML][HTML] Cardioprotective and anti-inflammatory effects of empagliflozin during treatment with doxorubicin: A cellular and preclinical study
V Quagliariello, C Coppola, D Rea, C Maurea… - Annals of …, 2019 - Elsevier
Background Empagliflozin (EMPA), a selective inhibitor of the sodium glucose co-transporter
2, reduces the risk of hospitalization for heart failure or cardiovascular death, as seen in the …
2, reduces the risk of hospitalization for heart failure or cardiovascular death, as seen in the …
Empaglifozin has cardioprotective and anti-inflammatory effects during doxorubicin treatment: A preclinical study.
N Maurea, V Quagliariello, C Coppola, D Rea… - 2019 - ascopubs.org
e23057 Background: Empagliflozin (EMPA), a selective inhibitor of the sodium glucose co-
transporter 2 (SGLT2), reduces the risk of hospitalization for heart failure or cardiovascular …
transporter 2 (SGLT2), reduces the risk of hospitalization for heart failure or cardiovascular …
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
V Quagliariello, M De Laurentiis, D Rea… - Cardiovascular …, 2021 - Springer
Background Empagliflozin (EMPA), a selective inhibitor of the sodium glucose co-transporter
2, reduced the risk of hospitalization for heart failure and cardiovascular death in type 2 …
2, reduced the risk of hospitalization for heart failure and cardiovascular death in type 2 …
Empagliflozin prevents doxorubicin-induced myocardial dysfunction
J Sabatino, S De Rosa, L Tammè, C Iaconetti… - Cardiovascular …, 2020 - Springer
Background Empagliflozin showed efficacy in controlling glycaemia, leading to reductions in
HbA1c levels, weight loss and blood pressure, compared to standard treatment. Moreover …
HbA1c levels, weight loss and blood pressure, compared to standard treatment. Moreover …
Use of emgliflozine in cardiotoxicity treatment. EMPACARD-treatment registry. Six-months follow-up
AJ Daniele, V Gregorietti, D Costa… - European Heart …, 2022 - academic.oup.com
Background Despite improvements in cancer management, cancer treatment related cardiac
dysfunction (CTRCD) is a growing medical problem that impact cancer patients' prognosis …
dysfunction (CTRCD) is a growing medical problem that impact cancer patients' prognosis …
P5716 Cardioprotective anti inflammatory effects of empaglifozin in doxorubicin induced cardiotoxicity: the role of leukotriene B4 and interleukin 1
N Maurea, V Quagliariello, C Coppola… - European Heart …, 2019 - academic.oup.com
Background Empagliflozin (EMPA), a selective inhibitor of the sodium glucose co-transporter
2 (SGLT2), reduces the risk of hospitalization for heart failure or cardiovascular death in type …
2 (SGLT2), reduces the risk of hospitalization for heart failure or cardiovascular death in type …
[HTML][HTML] Empagliflozin attenuates doxorubicin-induced cardiotoxicity by inhibiting the JNK signaling pathway
HY Chang, HC Hsu, YH Fang, PY Liu, YW Liu - Biomedicine & …, 2024 - Elsevier
Background Sodium-glucose cotransporter-2 inhibitors, such as empagliflozin, are pivotal
therapies for heart failure. However, the effect of empagliflozin on doxorubicin-related …
therapies for heart failure. However, the effect of empagliflozin on doxorubicin-related …
[HTML][HTML] Empagliflozin treatment of cardiotoxicity: A comprehensive review of clinical, immunobiological, neuroimmune, and therapeutic implications
Cancer and cardiovascular disorders are known as the two main leading causes of mortality
worldwide. Cardiotoxicity is a critical and common adverse effect of cancer-related …
worldwide. Cardiotoxicity is a critical and common adverse effect of cancer-related …
Empagliflozin significantly prevents the doxorubicin-induced acute cardiotoxicity via non-antioxidant pathways
VÖ Barış, AB Dinçsoy, E Gedikli, S Zırh… - Cardiovascular …, 2021 - Springer
Empagliflozin (EMPA) is a SGLT-2 inhibitor that has positive effects on cardiovascular
outcomes. In this study, we aim to evaluate the possible protective effects of EMPA against …
outcomes. In this study, we aim to evaluate the possible protective effects of EMPA against …
[PDF][PDF] Potential Role of Empagliflozin to Ameliorate Doxorubicin Induced Cardiotoxicity in Male Rats
RN Albakaa, FA Rizij, RMA Hassan - J. Med. Chem. Sci, 2023 - researchgate.net
Empagliflozin (EMPA), a selective inhibitor of the sodium-glucose co-transporter 2, is
especially effective at regulating blood-sugar levels [1]. Compared to conventional optimum …
especially effective at regulating blood-sugar levels [1]. Compared to conventional optimum …